FMS vs. DVA, SHC, PGNY, AGL, VMD, CO, MRAI, OTRK, MGRX, and BRTX
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), agilon health (AGL), Viemed Healthcare (VMD), Global Cord Blood (CO), Marpai (MRAI), Ontrak (OTRK), Mangoceuticals (MGRX), and BioRestorative Therapies (BRTX). These companies are all part of the "miscellaneous health & allied services, not elsewhere classified" industry.
DaVita (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
DaVita has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Fresenius Medical Care has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
In the previous week, Fresenius Medical Care had 6 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Fresenius Medical Care and 5 mentions for DaVita. Fresenius Medical Care's average media sentiment score of 1.13 beat DaVita's score of 0.63 indicating that DaVita is being referred to more favorably in the media.
DaVita has higher earnings, but lower revenue than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
DaVita has a net margin of 6.61% compared to DaVita's net margin of 2.48%. Fresenius Medical Care's return on equity of 68.52% beat DaVita's return on equity.
DaVita presently has a consensus target price of $144.67, suggesting a potential downside of 0.34%. Fresenius Medical Care has a consensus target price of $24.00, suggesting a potential upside of 13.26%. Given DaVita's higher possible upside, analysts plainly believe Fresenius Medical Care is more favorable than DaVita.
90.1% of DaVita shares are owned by institutional investors. Comparatively, 8.3% of Fresenius Medical Care shares are owned by institutional investors. 2.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
DaVita received 87 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.70% of users gave DaVita an outperform vote while only 53.99% of users gave Fresenius Medical Care an outperform vote.
Summary
DaVita beats Fresenius Medical Care on 13 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresenius Medical Care Competitors List
Related Companies and Tools
